Biopharma Venture Capital In Europe: Still Alive, And Starting To Wake Up

European VC is enjoying a revival -- of sorts. It was badly hit by the financial crisis, but now attractively low valuations, plus a continuing stream of opportunities, including Big Pharma spin-outs, are starting to lure some investors back, and provide validation for stalwarts who remained committed during the lean times.